One-Year Prospective Study on Clinical Experience and Acceptability of Etonogestrel Subdermal Contraceptive Implant (Implanon)

Background: Long-acting reversible contraceptives (LARCs) are among the most effective methods for preventing unintended pregnancies. The single-rod etonogestrel implant (Implanon) provides highly effective, reversible, and user-independent contraception. However, its long-term acceptability depends on user experience, side-effect profile, and quality of counselling. Objectives: The present study aimed to evaluate the clinical experience of women using the etonogestrel subdermal contraceptive implant, to assess its acceptability and one-year continuation rate, and to determine the pattern of adverse effects associated with its use in a tertiary care setting. Methods: A prospective observational study was conducted at Patna Medical College and Hospital, Patna, from February 2025 to January 2026. A total of 90 eligible women opting for Implanon were enrolled and followed for one year. Socio demographic data, adverse effects, satisfaction, and continuation status were recorded and analysed using descriptive statistics and chi-square testing. Results: The mean age of participants was 26.8 ± 4.9 years. Menstrual irregularity was the most frequently reported side effect (39.0%). The overall continuation rate at one year was 78.9% (95% CI: 69.3–86.6). Continuation was significantly higher among women without side effects compared with those experiencing side effects (88.2% vs 73.2%, p = 0.009). Conclusion: The etonogestrel implant is a safe, effective, and highly acceptable LARC with high continuation and satisfaction rates. Structured counselling and follow-up can further improve continuation.